Your browser doesn't support javascript.
loading
[Clinical Features and Prognostic Analysis of Newly Diagnosed Diffuse Large B-cell Lymphoma Combined with Hemophagocytic Syndrome].
Wei, Xiao-Fang; Feng, You-Fan; Fu, Yuan; Liu, Fei; Chen, Qiao-Lin; Zhang, Qi-Ke.
Afiliación
  • Wei XF; Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
  • Feng YF; Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
  • Fu Y; Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
  • Liu F; Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
  • Chen QL; Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
  • Zhang QK; Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 32(2): 466-469, 2024 Apr.
Article en Zh | MEDLINE | ID: mdl-38660853
ABSTRACT

OBJECTIVE:

To compare the clinical features and prognosis between newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with and without hemophagocytic syndrome (HPS).

METHODS:

The clinical data of 45 DLBCL patients in Gansu Provincial Hospital from January 2012 to December 2021 were retrospectively analyzed. The patients were divided into HPS group (15 cases) and non-HPS group (30 cases). The clinical features and prognosis of the two groups were compared, and survival analysis was performed using Kaplan-Meier method.

RESULTS:

Patients with HSP were mostly characterized by fever, cytopenia and splenomegaly. The levels of ferritin and soluble CD25 increased in all patients. The level of fibrinogen decreased in 66.67% patients, while triglyceride increased in 53.33% patients, and bone marrow hemophagocytosis occurred in 80.00% patients. Compared with non-HSP group, the proportions of patients with advanced stage (Ann Arbor stage III/IV) and lactate dehydrogenase (LDH) ≥240 U/L were higher in HSP group (both P < 0.05). The median survival time of HSP group was 8.0 months, which was significantly shorter than 45.5 months of non-HSP group (P < 0.001).

CONCLUSION:

The DLBCL patients with HPS have later Ann Arbor stage, higher LDH and shorter overall survival time compared with patients without HPS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Linfohistiocitosis Hemofagocítica Límite: Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Linfohistiocitosis Hemofagocítica Límite: Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: China